ArticleAnnals of surgical treatment and research2025
Combined CA19-9, CA125, and CEA to predict prognosis of patients with intrahepatic cholangiocarcinoma after radical surgery: a retrospective, multi-institutional study.
Article in Annals of surgical treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection.Journal of gastrointestinal oncology · 2026Article
- Comparative Analytical Performance and Clinical Agreement of Chemiluminescence Microparticle Immunoassay and Electrochemiluminescence Immunoassay for CA19-9: A Diagnostic Accuracy Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In intrahepatic cholangiocarcinoma (ICC), the interactions among CA19-9, CA125, and CEA are not yet fully understood. This study aims to investigate the relationship between a combined grading system of CA19-9, CA125, and CEA (3C grade) and the prognosis of ICC patients, as well as its predictive capability for prognosis. Methods: The patients were categorized into different 3C grades based on preoperative serum levels of CA19-9, CA125, and CEA to explore the relationship between 3C grade and overall survival (OS) and recurrence-free survival (RFS), assessing the predictive value of 3C grade for OS and RFS. Results: A total of 535 eligible patients were included and were classified into different 3C grade groups. Significant differences were observed among different 3C grade groups in clinical characteristics such as tumor size (P = 0.006) and lymph node metastasis (P = 0.006). The Kaplan-Meier curves demonstrated significant differences in OS and RFS among the different 3C grade groups (P < 0.001). The receiver operating characteristic curve analysis revealed that the 3C grade had superior predictive value for OS and RFS compared to individual tumor markers (P < 0.05 for each). Conclusion: This study revealed that the 3C grade was identified as an independent prognostic factor for OS and RFS after radical surgery of ICC, demonstrating superior predictive value for OS and RFS compared to single tumor markers. The 3C grade model holds promise to assist clinicians in preoperative assessment of ICC patients undergoing radical surgery, thereby aiding in the development of personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.